Introduction Arrow declarations have emerged as a distinctive mechanism in patent litigation, particularly within the UK pharmaceutical sector, with significant implications for royalty-bearing transactions and licensing strategies. An Arrow declaration is a court's declaratory judgment that a product or process was old or obvious (lacking novelty or

Equity kickers—warrants, options, convertible features, or other equity-linked instruments bundled with debt or investment transactions—serve as return enhancers across life sciences financing. The mechanism is straightforward: lenders or investors receive the right to purchase equity at a fixed price, creating asymmetric upside if the company's

Recent pharmaceutical royalty financings have increasingly featured "royalty tail" provisions. In a royalty monetization, an originator (typically a pharma or biotech company) sells a portion of its future royalty stream to an investor in exchange for upfront cash. A royalty tail typically means the investor's right

The final week of January 2026 delivered the largest licensing deal of the year so far, a collapsed mega-merger, and continued momentum in venture fundraising and IPO activity. AstraZeneca committed up to $18.5 billion for obesity assets from China, while Merck walked away from a potential $30 billion

2025-2026 Market Overview: Record Volume Reshapes the Landscape Before diving into the technical intricacies of liens, it is worth pausing to appreciate the sheer scale of the market these security interests now protect. The pharmaceutical royalty financing market reached a historic $10 billion in announced transaction value in 2025,

SLR Investment Corp. (NASDAQ: SLRC) is a New York-based business development company externally managed by SLR Capital Partners, a specialty finance platform with approximately $12 billion in assets under management. Founded in 2007 and publicly traded since its February 2010 IPO, SLRC operates as a closed-end investment company

Executive Summary Mendra, Inc. is a newly launched San Francisco-based biopharmaceutical company targeting high-unmet-need rare diseases. In January 2026, the company announced an oversubscribed $82 million Series A financing co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The startup&

The Gulf Cooperation Council (GCC) pharmaceutical industry is undergoing significant structural changes as sovereign wealth funds deploy capital and local manufacturers expand biosimilar portfolios and manufacturing capacity. The combined GCC market reached approximately $23.7 billion in 2024, with projections targeting $49 billion by 2033 at a 7.6% CAGR.

The Pension Fund Challenge—And Why Royalties Address It Defined benefit pension plans face a structural dilemma: actuarial assumptions of 6-7% annual returns must be met against a backdrop of compressed fixed income yields and elevated equity valuations. Traditional 60/40 portfolios no longer generate sufficient risk-adjusted returns

What Are Indication-Specific Royalties? Indication-specific royalties are royalty financing or licensing arrangements where payments are tied only to sales of a product in a particular indication (i.e. a specific therapeutic use or medical condition). In other words, if a drug or device is approved for multiple uses,